Skip to main content

$0.062 0.002 (3.33%)

High

$0.06

Low

$0.06

Trades

18

Turnover

$32,113

Volume

526,676
30 June 2023 at 3:59pm
Register to track DXB and receive email alerts.
DXB Announcements on Price Chart

Latest Announcements

Headline Date
Application for quotation of securities - DXB 29 June 2023 at 9:25am
Application for quotation of securities - DXB 29 June 2023 at 9:25am
Application for quotation of securities - DXB 29 June 2023 at 9:25am
Application for quotation of securities - DXB 29 June 2023 at 9:25am
Notification regarding unquoted securities - DXB 29 June 2023 at 9:20am
Notification regarding unquoted securities - DXB 29 June 2023 at 9:20am
Prospectus 26 June 2023 at 11:10am
Results of Meeting 20 June 2023 at 3:05pm
Application for quotation of securities - DXB 15 June 2023 at 3:15pm
Change of Director's Interest Notices - NW and SP 13 June 2023 at 1:00pm
Change in substantial holding 6 June 2023 at 3:20pm
Dimerix to present at BIO International Convention 6 June 2023 at 9:15am
Top 20 Option Holders & Distribution Schedule 5 June 2023 at 12:05pm
Notification regarding unquoted securities - DXB 5 June 2023 at 12:00pm
Application for quotation of securities - DXB 5 June 2023 at 11:45am
Dimerix Announces Update on Successful Capital Raise 5 June 2023 at 10:10am
Reminder of Closing Date for Non-Renounceable Rights Offer 26 May 2023 at 12:35pm
Application for quotation of securities - DXB 25 May 2023 at 3:45pm
Notification regarding unquoted securities - DXB 25 May 2023 at 3:35pm
Letter to Shareholders, Notice of Meeting & Proxy Form 22 May 2023 at 9:50am
Letter to Ineligible Foreign Shareholders 12 May 2023 at 9:45am
Letter to Nominees and Custodians 12 May 2023 at 9:45am
Despatch of Prospectus and Letter to Eligible Shareholders 12 May 2023 at 9:45am
Investor Webinar 4 May 2023 at 10:05am
Rights Issue Prospectus 4 May 2023 at 10:05am
Reinstatement to Official Quotation 4 May 2023 at 9:35am
Investor Presentation 4 May 2023 at 9:35am
Proposed issue of securities - DXB 4 May 2023 at 9:30am
Proposed issue of securities - DXB 4 May 2023 at 9:30am
Proposed issue of securities - DXB 4 May 2023 at 9:30am
Proposed issue of securities - DXB 4 May 2023 at 9:30am
Proposed issue of securities - DXB 4 May 2023 at 9:30am
Proposed issue of securities - DXB 4 May 2023 at 9:30am
Entitlement offer and Convertible Note to raise $12 million 4 May 2023 at 9:30am
Voluntary Suspension 3 May 2023 at 9:05am
Initial Director's Interest Notice - CS 2 May 2023 at 4:10pm
Dimerix Announces New Board Member 1 May 2023 at 9:30am
Trading Halt 1 May 2023 at 9:10am
Quarterly Appendix 4C and Activities Report 28 April 2023 at 5:10pm
Ceasing to be a substantial holder 21 April 2023 at 1:20pm
FSGS Study, Partnering & Commercialisation Investor Briefing 22 March 2023 at 9:10am
Half-Year Financial Report & Appendix 4D - 31 December 2022 27 February 2023 at 9:00am
DXB to Receive $2.8m in Prepayment of R&D Tax Incentive 17 February 2023 at 8:55am
Successful Completion of DSMB Review of Phase 3 FSGS Trial 9 February 2023 at 9:30am
Quarterly Appendix 4C and Activities Report 31 January 2023 at 9:15am
FDA Confirms Inclusion of Paediatrics in ACTION3 Study 12 January 2023 at 9:40am
Final Director's Interest Notice 28 December 2022 at 10:50am
Resignation of Non-Executive Chairman 23 December 2022 at 9:45am
DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved 15 December 2022 at 9:20am
CLARITY 2.0 COVID-19 Study Outcome 13 December 2022 at 9:10am
Register to track DXB and receive email alerts.